🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Viyash Scientific Limited VIYASH NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.viyash.com
Company Profile ↓
₹280.45
+48.99% 1Y
Mkt Cap₹12,251.48 Cr
P/E69.94
P/B4.24
52W High₹294.15
52W Low₹168.04
Book Value₹66.64
EPS (TTM)₹4.01

Company Overview

Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientific Limited operates as a subsidiary of CA Harbor Investments.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 82.1% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 34.1% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.17.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹3,420.31 Cr (+13.8% YoY); net profit ₹177.28 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +13.8%, earnings +663.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 34.1%, profit CAGR 82.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:34.10%
1 Year:13.75%

Compounded Profit Growth

5 Years:82.11%
1 Year:663.48%

Stock Price Performance

1 Year:+48.99%
6 Months:+45.70%
3 Months:+34.67%
1 Month:+13.38%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 89% of range
₹168.04 ₹294.15
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)57.25 · Neutral
Price Performance
1M+13.38%
3M+34.67%
6M+45.70%
1Y+48.99%
Valuation vs Sector

P/E of 69.94 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 34.1% over 5 years.
  • Profit CAGR of 82.1% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 69.9.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
69.94
Industry PE
39.97
Forward P/E
21.63
PEG Ratio
-
Book Value
₹66.64
Price to Book
4.24
P/S
3.63
EV/EBITDA
19.52
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
34.10%
Profit 5Y
82.11%
Revenue (YoY)
13.75%
Earnings (YoY)
663.48%

Profitability & Returns

ROCE
11.36%
ROE
6.09%
ROA
3.83%
Profit Margin
5.18%
Op Margin
12.30%
Gross Margin
54.31%
EPS (Latest Qtr)
₹1.17
EPS (TTM)
₹4.01

Balance Sheet & Liquidity

Debt/Equity
0.17
Quick Ratio
1.53
Current Ratio
2.38
Debt
₹489.76 Cr
Total Assets
₹4,628.39 Cr
Current Assets
₹2,254.55 Cr
Working Capital
₹1,308.65 Cr

Ownership

Promoter Holding
67.91%
Chg in Prom Hold
6.60%
FII / Inst Holding
7.01%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
₹12,251.48 Cr
Total Revenue (TTM)
₹3,420.31 Cr
EBITDA
₹651.87 Cr
Free Cash Flow
₹188.19 Cr
Operating Cash Flow
₹322.91 Cr
Shares Outstanding
₹43.69 Cr
Gross Margin
54.31%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 VIYASH Viyash Scientific Limited NSEPHARMA 280.45 69.94 ₹12,251.48 Cr 0.00% 11.36% 6.09% 34.10% 82.11%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 367.00 Cr333.00 Cr346.00 Cr329.00 Cr361.00 Cr390.00 Cr369.00 Cr-772.31 Cr441.42 Cr423.99 Cr858.41 Cr919.96 Cr
Cost of Revenue --------364.79 Cr234.55 Cr213.10 Cr390.93 Cr412.83 Cr
Gross Profit --------407.52 Cr206.87 Cr210.89 Cr467.48 Cr507.13 Cr
Operating Expenses 370.00 Cr341.00 Cr331.00 Cr307.00 Cr329.00 Cr348.00 Cr330.00 Cr-360.01 Cr173.52 Cr169.92 Cr349.88 Cr379.13 Cr
Operating Income -18.00 Cr-22.00 Cr07.00 Cr16.00 Cr26.00 Cr22.00 Cr-47.51 Cr33.35 Cr40.97 Cr117.60 Cr128.00 Cr
EBITDA -3.00 Cr-8.00 Cr15.00 Cr22.00 Cr32.00 Cr42.00 Cr39.00 Cr-48.75 Cr54.81 Cr56.13 Cr148.35 Cr200.17 Cr
Interest Expense 11.00 Cr10.00 Cr13.00 Cr13.00 Cr12.00 Cr16.00 Cr14.00 Cr-20.68 Cr14.16 Cr13.51 Cr16.75 Cr14.52 Cr
Pretax Income -89.00 Cr-56.00 Cr-3.00 Cr1.00 Cr3.00 Cr12.00 Cr8.00 Cr--36.66 Cr25.52 Cr27.16 Cr73.07 Cr125.24 Cr
Tax Provision -3.56 Cr21.28 Cr-3.69 Cr-6.17 Cr1.56 Cr2.88 Cr1.60 Cr--4.48 Cr7.95 Cr7.56 Cr24.55 Cr58.86 Cr
Net Income -92.00 Cr-35.00 Cr-7.00 Cr11.00 Cr1.00 Cr9.00 Cr6.00 Cr--26.24 Cr14.31 Cr14.74 Cr38.44 Cr52.11 Cr
Diluted EPS -3.75-1.40-0.340.33-0.040.260.10--0.610.560.580.871.17

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 443.00 Cr606.00 Cr684.00 Cr848.00 Cr1,039.00 Cr1,179.00 Cr1,362.00 Cr-1,418.28 Cr1,366.30 Cr3,006.84 Cr3,420.31 Cr
Cost of Revenue --------898.51 Cr813.12 Cr1,470.19 Cr1,562.73 Cr
Gross Profit --------519.76 Cr553.18 Cr1,536.65 Cr1,857.58 Cr
Operating Expenses 425.00 Cr550.00 Cr641.00 Cr765.00 Cr914.00 Cr1,009.00 Cr1,150.00 Cr-519.48 Cr516.16 Cr1,391.36 Cr1,436.99 Cr
Operating Income -14.00 Cr10.00 Cr3.00 Cr42.00 Cr83.00 Cr119.00 Cr161.00 Cr-28.50 L37.02 Cr145.29 Cr420.59 Cr
EBITDA 18.00 Cr56.00 Cr43.00 Cr83.00 Cr125.00 Cr170.00 Cr212.00 Cr--52.25 Cr53.32 Cr338.26 Cr651.87 Cr
Interest Expense 43.00 Cr38.00 Cr28.00 Cr33.00 Cr33.00 Cr36.00 Cr24.00 Cr-29.72 Cr46.42 Cr86.37 Cr69.21 Cr
Pretax Income -8.00 Cr-14.00 Cr-17.00 Cr444.00 Cr59.00 Cr94.00 Cr137.00 Cr--137.66 Cr-54.65 Cr13.18 Cr349.02 Cr
Tax Provision -3.20 Cr-2.66 Cr51.00 L13.32 Cr1.77 Cr12.22 Cr32.88 Cr--15.68 Cr-25.03 Cr-2.59 Cr124.37 Cr
Net Income -12.00 Cr-16.00 Cr-16.00 Cr431.00 Cr57.00 Cr82.00 Cr104.00 Cr--121.16 Cr-35.87 Cr23.22 Cr177.28 Cr
Diluted EPS -0.70-0.78-0.5717.301.972.813.84--4.88-1.440.534.01

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 908.00 Cr1,523.00 Cr1,896.00 Cr1,332.00 Cr1,378.00 Cr1,454.00 Cr1,386.00 Cr-1,529.12 Cr1,540.38 Cr1,601.95 Cr4,628.39 Cr
Current Assets --------789.89 Cr822.86 Cr873.73 Cr2,254.55 Cr
Cash & Equivalents --------41.57 Cr64.81 Cr62.66 Cr255.76 Cr
Inventory --------346.09 Cr346.23 Cr385.32 Cr803.20 Cr
Receivables --------340.96 Cr335.63 Cr363.17 Cr1,045.23 Cr
Total Liabilities --------779.93 Cr827.42 Cr831.58 Cr1,513.66 Cr
Current Liabilities --------558.76 Cr626.99 Cr505.00 Cr945.90 Cr
Long Term Debt --------150.11 Cr142.72 Cr273.88 Cr302.10 Cr
Total Debt 473.00 Cr312.00 Cr416.00 Cr305.00 Cr325.00 Cr343.00 Cr277.00 Cr-443.60 Cr487.69 Cr481.24 Cr489.76 Cr
Total Equity 91.00 Cr946.00 Cr977.00 Cr648.00 Cr706.00 Cr687.00 Cr728.00 Cr-698.78 Cr656.56 Cr704.47 Cr2,911.06 Cr
Shares Outstanding --------24.94 Cr24.94 Cr25.03 Cr43.69 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -24.00 Cr-0-7.00 Cr45.00 Cr116.00 Cr115.00 Cr115.00 Cr-16.81 Cr30.59 Cr344.80 Cr322.91 Cr
Investing Cash Flow -157.00 Cr-310.00 Cr-116.00 Cr7.00 Cr-68.00 Cr-72.00 Cr10.00 Cr--64.96 Cr-5.92 Cr-447.21 Cr-84.12 Cr
Financing Cash Flow 179.00 Cr309.00 Cr147.00 Cr-57.00 Cr-20.00 Cr-43.00 Cr-139.00 Cr-32.23 Cr-1.44 Cr87.03 Cr-123.33 Cr
Capital Expenditure -113.00 Cr-63.00 Cr-75.00 Cr-45.00 Cr-24.00 Cr-40.00 Cr-45.00 Cr--86.18 Cr-30.81 Cr-108.05 Cr-134.72 Cr
Free Cash Flow -137.00 Cr-63.00 Cr-82.00 Cr092.00 Cr75.00 Cr70.00 Cr--69.37 Cr-21.20 L236.75 Cr188.19 Cr
Net Change in Cash -1.00 Cr-2.00 Cr24.00 Cr-5.00 Cr28.00 Cr0-14.00 Cr--15.92 Cr23.24 Cr-15.38 Cr115.46 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------36.6%40.5%51.1%54.3%
Operating Margin % -3.2%1.7%0.4%5.0%8.0%10.1%11.8%-0.0%2.7%4.8%12.3%
Net Margin % -2.7%-2.6%-2.3%50.8%5.5%7.0%7.6%--8.5%-2.6%0.8%5.2%
ROE % -13.2%-1.7%-1.6%66.5%8.1%11.9%14.3%--17.3%-5.5%3.3%6.1%
ROCE % --------0.0%4.1%13.2%11.4%

Shareholding Pattern

Insiders
67.91%
Institutions
7.01%
Public Float
21.84%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VIYASH

Google News Wed, 24 Jun 2026

VIYASH Stock Price and Chart — NSE:VIYASH - TradingView

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE14QjcxYzRZc1hqaERHRUJtcm5BSl9RTG05SGdqU0tnZ0xKRjNvUC1ZN1J4LUZRc3EyVjYwa25IYi0zV2xpSTdXUnNpVzA1T0xESHRYYVNYRDdNM3M?oc=5" target="_blank">VIYASH Stock Price and Chart — NSE:VIYASH</a…

Google News Wed, 27 May 2026

Viyash Scientific's (NSE:VIYASH) Earnings Are Of Questionable Quality - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxOWmZFQm1CTFl4S3dCU2d6TVU5SlB3SmpJVW13YTRqbEhXR1hNVDBWVmVyeFVBUW9PbjdCNUZNMXhXbFUwek5hOWFwcHNoNjlrV2hsdTM0b0xrYmZabWd5VmROdHVZZUZtd1BndjRLRzRhX2RYaVRINWx1RFZZVDlqTEdGV0NaOE9ZZjNacl…

Google News Fri, 26 Jun 2026

Viyash Scientific Limited Actuals & Estimates (NSE:VIYASH) - TradingView

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxOc0FsSl9JTG9SVzV4QUZfMjR0b0Npd1VUZDJIeUVwcGVIaEdPcVk3NGd4YnJhSkRXLXFsLWZqMXQ4b2tIeHZKNjFnQXRLOUE2SkR2bE1NbGE4M1F1SWJ4T2NQYU94NzJTRUtSZkEyZUFOSG1uM29yME0wSWc2LVlSUXUwQnI?oc=5" targ…

Google News hu, 08 Jan 2026

Sequent Scientific Limited has Changed its Name to Viyash Scientific Limited - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPX2JEekx2ZUdIZGk4OEQ1VlozYm5xYTh6VUhISzlTX0Ytd1hOcmlVeHFJbERFVnNGNXRsRHg3d3k3YjhLZ0EzMnFJZXRwTWFTdV9yYUdOc1dueGQ3MldmRjg4VzhLSVVQNlR3Vmcwc25wMnQ2RV9JSFRqMEN2WFEtb0FSMjhKVE5jZUtYdG…

Google News Wed, 08 Jul 2026

SEBI warns Viyash Scientific over SDD maintenance gaps - scanx.trade

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNUkRONjlIeTI0eDdNNEdOQ19IeEZyZUsxUjN0SVROMUxhNUQ2Z3lEcGlvcm1IT1RvLUVTRS1wOWk2X0tFdUJKOXIyaFhVLThqR1JXRHZsQXZPSVdvdlNhbDh2U2FTUFZka0s0bGxKYXJ1M1ZOV3FkdnYtak1zY0NEMTY3UnNOUDB1UjdfWE…

Google News Sat, 23 May 2026

Viyash Scientific Limited Just Missed Earnings - But Analysts Have Updated Their Models - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTE1yRFQ2LThObWlLVmtoYXVaQzNzRnlNUHlzaDlYTklubzJSMzctS2FPNF92bHJ6NFE4OC1uanRQR09SbTRwLVBERkpKdWFIaTgyTVExUUd2UVBoZ0dfb05iMHBxMnFmNVlzTmtlWFJoWi1iWUlWYVczZE1OQnVxa05qanZaX2gtY0VXQW…

VIYASH — Frequently Asked Questions

What is the current share price of Viyash Scientific Limited (VIYASH)?

As of 2026-07-15 09:52 IST, Viyash Scientific Limited (VIYASH) trades at ₹280.45 on NSE. Its 52-week range is ₹168.04 to ₹294.15.

What is the market capitalisation of VIYASH?

Viyash Scientific Limited (VIYASH) has a market capitalisation of ₹12,251.48 Cr on NSE.

What is the P/E ratio of VIYASH?

VIYASH trades at a trailing price-to-earnings (P/E) ratio of 69.94. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 4.24.

What is the return on equity (ROE) of VIYASH?

VIYASH has a return on equity (ROE) of 6.09%. Its return on capital employed (ROCE) is 11.36%.

Is VIYASH a good stock to buy?

This page provides a data-driven analysis of Viyash Scientific Limited (VIYASH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space